Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Scientists hunt for clues to deadly sepsis complication in european patients

NCT ID NCT06986798

Knowledge-focused Sponsor: Bayer Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study examined 150 adults with sepsis in the ICU to find blood markers that signal when the condition turns into a dangerous clotting problem called DIC. Researchers collected blood samples and hospital data over up to 56 days, but did not test any new treatments. The goal is to better understand how and why DIC develops in sepsis patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

150 people

The number who actually took part.

Started

Jan 2025

Finished

May 2026

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Participant must be 18 years of age inclusive, at the time of signing the informed consent. * Participants with diagnosed sepsis according to sepsis-3 definition. * Participants with documented suspected origin of infection. * Informed consent of capable participant or, in case of participant being incapable of giving informed consent, consent for study inclusion will be sought according to applicable laws and regulations. Exclusion Criteria: * Patients deferred from other Intensive Care Units (ICUs). * Patients longer than 24 hours on ICU. * Known coagulation disorder. * Ongoing active clinically significant bleeding. * Participants experienced trauma or major surgery (within 4 weeks). * Active malignancy. * Decompensated liver impairment Child-Pugh Class C. * Moribund patients not expected to survive 24 hours (clinical decision). * Ongoing therapeutic anticoagulation (prophylactic dose of Unfractionated Heparin \[UFH\]/Low Molecular Weight Heparin \[LMWH\] is allowed) or antiplatelet therapy (except low dose \[≤100 mg\] acetyl salicylic acid \[ASA\]). If previously named treatment can be stopped the participants will be eligible if a "wash out"-time of five half-lives is applied before start of study. * Patients who have received any investigational drug involving pharmacological interventions, or biological or cell therapy interventions or prohibited therapy within 28 days or five half-lives, whichever is longer, prior to screening/baseline. * Any reason that would make participation unadvisable, at the discretion of the investigator.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Sepsis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

disseminated intravascular coagulation infectious disease with sepsis Sepsis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Sepsis Sepsis associated dic

Contacts and locations

Locations

  • AZ Groeninge - Campus Kennedylaan

    Kortrijk, 8500, Belgium

  • Azienda Ospedaliero-Universitaria Di Bologna IRCCS_Policlinico Sant'Orsola - Anestesia e TI Polivalente

    Bologna, 40138, Italy

  • Azienda Socio Sanitaria Territoriale Santi Paolo e Carlo_Ospedale S. Carlo - Anestesia e Rianimazione

    Milan, 20153, Italy

  • CHRU de Tours - Hôpital Bretonneau - Médecine Intensive Réanimation

    Tours, Centre-Val de Loire, 37044, France

  • Centre Hospitalier Départemental Vendée - Service de réanimation polyvalente

    La Roche-sur-Yon, Pays de la Loire Region, 85000, France

  • Centre Hospitalier Universitaire (CHU) de Liege - Domaine Universitaire du Sart Tilman

    Liège, 4000, Belgium

  • Centre Hospitalier Universitaire d'Angers - Médecine Intensive Réanimation et Médecine Hyperbare

    Angers, Pays de la Loire Region, 49100, France

  • Centre Hospitalier Universitaire de Limoges Dupuytren 1 - Service de réanimation polyvalente

    Limoges, New Aquitaine, 87042, France

  • Clinique Saint-Pierre d'Ottignies - Intensive Care

    Ottignies-Louvain-la-Neuve, 1340, Belgium

  • Fondazione Policlinico Universitario Agostino Gemelli IRCCS - Anestesia, Rianimazione, Terapia Intensiva e Tossicologia Clinica

    Roma, 00168, Italy

  • Hopital Hotel Dieu Nantes - Service de Médecine Intensive Réanimation

    Nantes, Pays de la Loire Region, 44000, France

  • Hopitaux Universitaires de Strasbourg Nouvel Hopital Civil - Service de Médecine Intensive Réanimation

    Strasbourg, Grand Est, 67091, France

  • Hospital Clinico San Carlos | Unidad de Cuidados Intensivos

    Madrid, 28040, Spain

  • Hospital Universitari Vall D Hebron | Unidad de Cuidados Intensivos

    Barcelona, 08035, Spain

  • Hospital Universitario Central De Asturias | Unidad de Cuidados Intensivos

    Oviedo, Principality of Asturias, 33011, Spain

  • Hospital Universitario De Getafe | Unidad de Cuidados Intensivos

    Getafe, Madrid, 28905, Spain

  • Hospital Universitario Virgen Del Rocio S.L. | Unidad de Cuidados Intensivos

    Seville, 41013, Spain

  • Humanitas Mirasole S.p.A. - Anestesia e Terapie Intensive

    Rozzano, 20089, Italy

  • Hôpital Raymond-Poincaré - Service de Médecine Intensive - Réanimation, Médecine Hyperbare

    Garches, Île-de-France Region, 92380, France

  • Kliniken der Stadt Köln gGmbH - Krankenhaus Merheim - Lungenklinik

    Cologne, North Rhine-Westphalia, 51109, Germany

  • Klinikum der Universität München AöR - Klinik für Anaesthesiologie (Campus Großhadern)

    München, 81377, Germany

  • Maasstad

    Rotterdam, South Holland, 3079 DZ, Netherlands

  • MedUni Graz | Innere Medizin, ICU

    Graz, 8036, Austria

  • MedUni Innsbruck | Innere Medizin I, Internistische Intensiv- und Notfallmedizin

    Innsbruck, Tyrol, 6020, Austria

  • MedUni Wien | Univ. Klinik für Klinische Pharmakologie

    Vienna, 1090, Austria

  • Medisch Spectrum Twente - Intensive Care

    Enschede, Overijssel, 7512 KZ, Netherlands

  • RKH Klinikum Ludwigsburg

    Ludwigsburg, 71640, Germany

  • Universitaetsklinikum Carl Gustav Carus an der Technischen Universitaet Dresden | Medizinische Klinik I - FB Haemostaseologie

    Dresden, 01307, Germany

  • Universitaetsklinikum Essen | Klinik für Anaesthesiologie und Intensivmedizin

    Essen, 45147, Germany

  • Universitair Medisch Centrum St. Radboud

    Nijmegen, 6500HB, Netherlands

  • Universite Catholique de Louvain (UCL) - Cliniques Universitaires Saint-Luc

    Woluwe-Saint-Lambert, 1200, Belgium

More trials for these conditions

Other studies related to the condition(s) this trial covers.